Clinical Trials Browser

Enrolling by invitation × Stomach Neoplasms × Genitourinary × Clear all

NCT07218003 2026-05-04

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07023848 2025-06-17

PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors

Phase EARLY_PHASE1 Enrolling by invitation

10 enrolled

BreastGastrointestinalGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT07023861 2025-06-17

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

Phase EARLY_PHASE1 Enrolling by invitation

20 enrolled

BreastGastrointestinalGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Stomach Neoplasms